Seeking Alpha

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Genotypic Status Identified as a Significant Predictor of Risk and Left Ventricular Mass Index May Serve as a Surrogate Marker for Poor Long-Term Outcomes SOUTH SAN FRANCISCO, Calif., Aug. 31, 2025 ...
Nasdaq

Tenaya Therapeutics Announces Interim Findings from RIDGE Study, the Largest Natural History Study of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya Therapeutics has announced interim data from its RIDGE natural history study, the largest research effort to date on arrhythmogenic right ventricular cardiomyopathy (ARVC) associated with ...
Seeking Alpha

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients ...
News Medical

Understanding the natural history of SCN8A-related epilepsy disorders

Researchers from the Epilepsy Neurogenetics Initiative (ENGIN) at Children's Hospital of Philadelphia (CHOP) have completed a comprehensive natural history study of SCN8A-related disorders, which ...
PharmExec

Real-World Data Brings New Insights to Natural History of Disease Studies

A key advantage of using RWD in a natural history study is gaining diverse and representative data. RWD covers broad patient populations, including those with comorbidities, various age groups, and ...